CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its plan to release second quarter 2024 financial results on August 14, 2024, before the market opens. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day.
Investors and interested parties can access the conference call through the following options:
- Domestic: 1-877-270-2148
- International: 1-412-902-6510
- Webcast: Available via provided link
This announcement indicates CorMedix's commitment to transparency and shareholder communication, providing an opportunity for stakeholders to gain insights into the company's financial performance and recent developments.
CorMedix Inc. (Nasdaq: CRMD), un'azienda biofarmaceutica specializzata in prodotti terapeutici per malattie potenzialmente letali, ha annunciato il suo piano di pubblicare i risultati finanziari del secondo trimestre 2024 il 14 agosto 2024, prima dell'apertura del mercato. L'azienda ospiterà anche una conferenza telefonica di aggiornamento aziendale alle 8:30 AM ora orientale nello stesso giorno.
Gli investitori e le parti interessate possono accedere alla conferenza telefonica attraverso le seguenti opzioni:
- Locale: 1-877-270-2148
- Internazionale: 1-412-902-6510
- Webcast: Disponibile tramite il link fornito
Questo annuncio indica l'impegno di CorMedix verso la trasparenza e la comunicazione con gli azionisti, offrendo un'opportunità per le parti interessate di ottenere informazioni sulle performance finanziarie dell'azienda e sui recenti sviluppi.
CorMedix Inc. (Nasdaq: CRMD), una empresa biofarmacéutica especializada en productos terapéuticos para enfermedades potencialmente mortales, ha anunciado su plan para publicar los resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024, antes de que abra el mercado. La empresa también llevará a cabo una conferencia telefónica de actualización corporativa a las 8:30 AM, hora del Este, el mismo día.
Los inversores y partes interesadas pueden acceder a la conferencia telefónica a través de las siguientes opciones:
- Nacional: 1-877-270-2148
- Internacional: 1-412-902-6510
- Webcast: Disponible a través del enlace proporcionado
Este anuncio indica el compromiso de CorMedix con la transparencia y la comunicación con los accionistas, brindando una oportunidad para que los interesados obtengan información sobre el desempeño financiero de la empresa y los desarrollos recientes.
CorMedix Inc. (Nasdaq: CRMD)는 생명을 위협하는 질병을 위한 치료 제품을 전문으로 하는 바이오 제약 회사로, 2024년 2분기 재무 결과를 2024년 8월 14일, 시장 개장 전에 발표할 계획을 발표했습니다. 회사는 같은 날 오전 8시 30분(동부 표준시)에 기업 업데이트 전화 회의를 개최할 예정입니다.
투자자 및 관심 있는 당사자는 다음의 방법으로 전화 회의에 참여할 수 있습니다:
- 국내: 1-877-270-2148
- 국제: 1-412-902-6510
- 웹캐스트: 제공된 링크를 통해 가능
이 발표는 CorMedix가 투명성과 주주 소통에 대한 강한 의지를 가지고 있음을 나타내며, 이해 관계자들이 회사의 재무 성과와 최근 발전 사항에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
CorMedix Inc. (Nasdaq: CRMD), une entreprise biopharmaceutique spécialisée dans les produits thérapeutiques pour les maladies potentiellement mortelles, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le 14 août 2024, avant l'ouverture du marché. L'entreprise organisera également un appel conférence de mise à jour sur l'entreprise à 8h30, heure de l'Est, le même jour.
Les investisseurs et les parties intéressées peuvent accéder à l'appel conférence par les options suivantes :
- National : 1-877-270-2148
- International : 1-412-902-6510
- Webcast : Disponible via le lien fourni
Cette annonce indique l'engagement de CorMedix envers la transparence et la communication avec les actionnaires, offrant une opportunité aux parties prenantes d'obtenir des informations sur les performances financières de l'entreprise et les développements récents.
CorMedix Inc. (Nasdaq: CRMD), ein biopharmazeutisches Unternehmen, das auf therapeutische Produkte für lebensbedrohliche Krankheiten spezialisiert ist, hat angekündigt, seine finanziellen Ergebnisse für das zweite Quartal 2024 am 14. August 2024, vor Markteröffnung, zu veröffentlichen. Das Unternehmen wird an diesem Tag um 8:30 Uhr Eastern Time auch einen Unternehmens-Update-Konferenzanruf abhalten.
Investoren und interessierte Parteien können über folgende Optionen auf den Konferenzanruf zugreifen:
- Inland: 1-877-270-2148
- International: 1-412-902-6510
- Webcast: Verfügbar über den bereitgestellten Link
Diese Ankündigung zeigt das Engagement von CorMedix für Transparenz und Kommunikation mit den Aktionären und bietet den Interessengruppen die Möglichkeit, Einblicke in die finanzielle Leistung des Unternehmens und die neuesten Entwicklungen zu gewinnen.
- Timely disclosure of quarterly financial results
- Hosting a corporate update conference call for investors
- None.
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
Wednesday, August 14th @ 8:30am ET
| Domestic: | 1-877-270-2148 |
| International: | 1-412-902-6510 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will CorMedix (CRMD) report its Q2 2024 financial results?
What time is CorMedix's (CRMD) Q2 2024 earnings call scheduled for?
How can investors access CorMedix's (CRMD) Q2 2024 earnings call?
What is CorMedix's (CRMD) main business focus?
